“The present situation has exposed some structural weaknesses inside the EU’s medicines offer chain along with a large dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides explained. She suggested that provide chain problems be tackled within an EU pharmaceutical method envisioned for being launched